secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001493152-24-031356
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra Q2 net loss narrows to $2.6M; completes $10M offering, pipeline milestones set
--------------------------------------------------------------------------------

- Net loss of $2.6M improved from $5.1M in Q2 2023; cash and equivalents $0.8M as of June 30.
- Completed $10M follow-on offering, expected to fund operations into 2025.
- R&D expenses $1.1M (up from $0.8M); G&A $1.5M (up from $0.8M); service revenue $7,500 (down from $172k).
- Expects to dose first Netherton syndrome patient with ATR-12 in Q3 2024; plans IND for ATR-04 for EGFRi rash.
- Anticipates initial safety data from ATR-12 Phase 1b by year-end 2024, topline data by mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000149315224031356/0001493152-24-031356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000149315224031356/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer